Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoring.
Cancer
Chemotherapy
Continuous glucose monitoring
Diabetes
Hypoglycemia
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
25
10
2022
accepted:
05
01
2023
pubmed:
14
1
2023
medline:
25
3
2023
entrez:
13
1
2023
Statut:
ppublish
Résumé
The aim of our study was to assess, with Continuous Glucose Monitoring (CGM), exhaustive information on the glucose profile in people with diabetes starting chemotherapy. We also evaluated the adaptation of glucose-lowering drugs following analysis of CGM recordings. Eighty-five people with diabetes starting chemotherapy were included in the ONCODIAB study. A CGM was worn for up to fourteen days in blinded mode before and after the diabetologist's intervention to evaluate the impact of modifying the glucose-lowering drugs. Time spent in range was 67.2 ± 24.2%. Time below the target glucose range (TBR) (< 70 mg/dl) was 8.9% in all the study population. TBR was significantly higher in patients treated with at least one drug due to the risk of hypoglycemia compared to the others (11.5% vs. 4.4%, p = 0.009). Sixty-five patients had available sensor data for the two recordings. Forty-one patients (51.9%) saw a decrease in their antidiabetic treatment after the diabetologist's intervention guided by the first CGM recording. We observed a significant reduction in the time spent below the target glucose range (70-55 mg/dl) between the two CGM recordings (10.3 ± 14.6% vs. 6.3 ± 9.4%, p = 0.016 and 3.8 ± 8.4% vs. 1.2 ± 2.9%, p = 0.012, respectively). CGM use in blinded mode could be an interesting tool to reduce the risk of hypoglycemia in people with diabetes starting chemotherapy. Our findings fully support the recommendation that assessing hypoglycemia risk should be mandatory in patients with diabetes before starting chemotherapy.
Identifiants
pubmed: 36637528
doi: 10.1007/s00592-023-02032-z
pii: 10.1007/s00592-023-02032-z
doi:
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
545-552Informations de copyright
© 2023. Springer-Verlag Italia S.r.l., part of Springer Nature.
Références
Joharatnam-Hogan N, Chambers P, Dhatariya K, Board R; the Joint British Diabetes Society for Inpatient Care (JBDS), UK Chemotherapy Board (UKCB) (2022) A guideline for the outpatient management of glycaemic control in people with cancer. Diabet Med 39:e14636
pubmed: 34240470
Jing L, Ni-ya N, Qun-xian R et al (2017) Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease. BMC Cancer 17:517
doi: 10.1186/s12885-017-3510-3
Nik-Ahd F, Howard LE, Eisenberg AT et al (2019) Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: results from the search database. Cancer 125:2861–2867
pubmed: 31034601
Shariff AI, Syed S, Shelby RA et al (2019) Novel cancer therapies and their association with diabetes. J Mol Endocrinol 62:R187–R199
doi: 10.1530/JME-18-0002
pubmed: 30532995
American Diabetes Association (2020) Diabetes technology: standards of medical care in diabetes-2020. Diabetes Care 43:S77-88
doi: 10.2337/dc20-S007
Battelino T, Danne T, Bergenstal RM et al (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42:1593–1603
doi: 10.2337/dci19-0028
pubmed: 31177185
pmcid: 6973648
Wada E, Onoue T, Kobayashi T et al (2020) Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diab Res Care 8:e001115
doi: 10.1136/bmjdrc-2019-001115
pubmed: 32518063
pmcid: 7292039
Haak T, Hanaire H, Ajjan R et al (2017) Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 8:55–73
doi: 10.1007/s13300-016-0223-6
pubmed: 28000140
Ashley L, Kassim S, Kellar I et al (2022) Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians. BMJ Open 12:e060402
doi: 10.1136/bmjopen-2021-060402
pubmed: 35193924
pmcid: 8867345
Hershey DS, Given B, Given C, et al (2014) Predictors of diabetes self-management in older adults receiving chemotherapy. Cancer Nurs 37:97–105
doi: 10.1097/NCC.0b013e3182888b14
pubmed: 23519039
Pinheiro LC, Soroka O, Kern LM, et al (2020) Diabetes care management patterns before and after a cancer diagnosis: a SEER-medicare matched cohort study. Cancer 126:1727–1735
doi: 10.1002/cncr.32728
pubmed: 31999848
Zanders MM, van Herk-Sukel MP, Herings RM et al (2015) Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia 58:951–960
doi: 10.1007/s00125-015-3497-8
pubmed: 25638246
Lee AK, Warren B, Lee CJ et al (2018) The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care 41(1):104–111
doi: 10.2337/dc17-1669
pubmed: 29127240
Worndl E, Fung K, Fischer HD et al (2018) Preventable diabetic complications after a cancer diagnosis in patients with diabetes: a population-based cohort study. JNCI Cancer Spectr 2:pky008
doi: 10.1093/jncics/pky008
pubmed: 29795802
pmcid: 5954615
Vigersky R, Shrivastav M (2017) Role of continuous glucose monitoring for type 2 in diabetes management and research. J Diabetes Complicat 31(1):280–287
doi: 10.1016/j.jdiacomp.2016.10.007
Galindo RJ (2020) Comparison of the freestyle libre pro flash continuous glucose monitoring (CGM) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen. Diabetes Care 43:2730–2735
doi: 10.2337/dc19-2073
pubmed: 32641372
pmcid: 7809713
Ragni A, Retta F, Arvat E et al (2021) Diabetes in cancer patients: risks, goals and management. Front Horm Res 54:103–114
doi: 10.1159/000513807
pubmed: 33556942
Lavdaniti M, Michalopoulou S, Owens DA et al (2021) The impact of comorbid diabetes type 2 on quality of life in cancer patients undergoing chemotherapy. Endocr Metab Immune Disord Drug Targets 21:1017–1024
doi: 10.2174/1871530320666200729151715
pubmed: 32727340